2024
MR-guided stereotactic radiation therapy for head and neck cancers
Wang H, Yang J, Lee A, Phan J, Lim T, Fuller C, Han E, Rhee D, Salzillo T, Zhao Y, Chopra N, Pham M, Castillo P, Sobremonte A, Moreno A, Reddy J, Rosenthal D, Garden A, Wang X. MR-guided stereotactic radiation therapy for head and neck cancers. Clinical And Translational Radiation Oncology 2024, 46: 100760. PMID: 38510980, PMCID: PMC10950743, DOI: 10.1016/j.ctro.2024.100760.Peer-Reviewed Original ResearchAdapt-to-shapeStereotactic body radiation therapyIMRT plansVMAT plansTarget coverageMR-LinacPlan qualityAdapt-to-shape workflowElekta Unity MR-linacMonaco treatment planning systemSoft tissue contrastVMAT treatment plansTreatment planning systemUnity MR-linacCritical organ dosesMR-guided radiotherapyHead and neckAdapt-to-positionRadiation therapyMean doseVarian TrueBeamTrueBeam STxOAR dosesDosimetric differencesElekta UnityClinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy
Maroongroge S, Mohamed A, Nguyen C, De la Vega J, Frank S, Garden A, Gunn B, Lee A, Mayo L, Moreno A, Morrison W, Phan J, Spiotto M, Court L, Fuller C, Rosenthal D, Netherton T. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy. Physics And Imaging In Radiation Oncology 2024, 29: 100540. PMID: 38356692, PMCID: PMC10864833, DOI: 10.1016/j.phro.2024.100540.Peer-Reviewed Original ResearchLymph node levelsAI contoursClinical acceptanceSwallowing structuresComputed tomographyHead and neck radiotherapy patientsHead and neckMedian Dice similarity coefficientLevels I-VDice similarity coefficientRadiotherapy patientsCT scanManual contouringLymphComplex anatomyCT imagesCohortI-VPatientsChewingSimilarity coefficientAnatomyRadiotherapyHeadNode level
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatients